Tarsus Pharmaceuticals Inc

+0.02 (+0.07%)
Products, Strategic Combinations

Tarsus Pharmaceuticals And Lianbio Announce Strategic Partnership To Develop And Commercialize TP-03 In Greater China For Treatment Of Demodex Blepharitis And Meibomian Gland Disease

Published: 03/29/2021 21:06 GMT
Tarsus Pharmaceuticals Inc (TARS) - Tarsus Pharmaceuticals and Lianbio Announce Strategic Partnership to Develop and Commercialize Tp-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease.
Tarsus Pharmaceuticals, Inc. - As Part of Strategic Partnership, Lianbio to Obtain Exclusive Rights to Develop, Commercialize Tp-03 in Greater China.
Tarsus Pharmaceuticals, Inc. - Will Receive a $15 Million Upfront Payment, May Also Receive Up to $185 Million in Development and Commercialization Milestones.
Tarsus Pharmaceuticals, Inc. - May Receive a Minority Equity Stake in Lianbio Ophthalmology, Which Will Vest Upon Achievement of Certain Milestones.